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RECQL1 andWRN helicases in the human RecQ helicase family participate in maintaining
genome stability, DNA repair, replication, and recombination pathways in the cell cycle.They
are expressed highly in rapidly proliferating cells and tumor cells, suggesting that they have
important roles in the replication of a genome. Although mice deﬁcient in these helicases
are indistinguishable from wild-type mice, their embryonic ﬁbroblasts are sensitive to DNA
damage. In tumor cells, silencing the expression of RECQL1 or WRN helicase by RNA
interference induces mitotic catastrophe that eventually kills tumor cells at the mitosis
stage of the cell cycle. By contrast, the same gene silencing by cognate small RNA
(siRNA) never kills normal cells, although cell growth is slightly delayed. These ﬁndings
indicate that RECQL1 andWRNhelicases are idealmolecular targets for cancer therapy.The
molecular mechanisms underlying these events has been studied extensively, which may
help development of anticancer drugs free from adverse effects by targeting DNA repair
helicases RECQL1 andWRN.As expected, the anticancer activity of conventional genotoxic
drugs is signiﬁcantly augmented by combined treatment with RECQL1- or WRN-siRNAs
that prevents DNA repair in cancer cells. In this review, we focus on studies that clariﬁed
the mechanisms that lead to the speciﬁc killing of cancer cells and introduce efforts to
develop anticancer RecQ-siRNA drugs free from adverse effects.
Keywords: RecQ helicases, genome instability, mitotic catastrophe, RECQL1-siRNA,WRN-siRNA, anticancer drug
candidates, chemotherapy, DDS
INTRODUCTION
The RecQ helicase family is conserved in all organisms and partic-
ipates in maintaining the genomic integrity of cells. Microorgan-
isms, such as Escherichia coli and Saccharomyces cerevisiae, contain
only one RecQ helicase, but higher eukaryotes have more than
one RecQ helicase. In human cells, the RecQ helicase family com-
prises ﬁve DNA helicases: RECQL1 (also known as RECQL or
RECQ1), Bloom syndrome (BLM), Werner syndrome (WRN),
Rothmund–Thomson syndrome (RTS; also known as RECQL4)
and RECQL5 (Furuichi, 2001; Hickson, 2003; Shimamoto et al.,
2004). These RecQ helicases are expressed in the nucleus, partici-
pate in DNA repair during cell proliferation and are up-regulated
at the time of DNA replication (Kawabe et al., 2000; Brosh, 2013).
BLM,WRN, and RTS syndromes are recessive genetic disorders of
humans causedby loss of functionbyBLM(Ellis et al.,1995),WRN
(Yu et al., 1996), and RTS helicases (Kitao et al., 1998, 1999, 2002;
Lindor et al., 2000), respectively, and are characterized by genomic
instability in patient cells, predisposition to various cancers and
accelerated onset of aging phenotypes. RECQL1 and RECQL5
helicases, however, have no association with mutations of human
disorders.
Thebiochemical functionof DNAhelicase is to unwinddouble-
stranded DNA to single-stranded DNAs, responding to cellular
DNA metabolisms, such as DNA replication and repair of DNA
damage (Sharma et al., 2006; Bernstein et al., 2010). Cells in the
process of replication have various endogenous DNA damage in
the chromosomes resulting from base-mismatch, deletion, DNA
double-strand break (DSB) or from replication errors caused by
stalled replication forks and other anomalous DNA structures,
such as G-quadruplex (G4) DNA. DNA damage also includes
damages generated exogenously by environmental mutagens, such
as ionic radiation, reactive oxygen, and genotoxic compounds.
Thus, the process of DNA replication associates with many errors
that expose growing cells to a risk of acquiring mutations. In
proliferating cells, however, cellular DNA damage checkpoints
coordinate an arrest at G1, intra-S, and G2 of the cell-cycle
to allow the DNA repair process to eventually avoid mitotic
catastrophe or mitosis of cells having unrepaired DNA damage.
Thus, the cellular systems responsible for genome stabilization,
such as DNA repair pathways and cell-cycle checkpoint func-
tions, are indispensable for survival and proliferation of cells
(Zhou and Elledge, 2000; Nyberg et al., 2002; Helleday et al.,
2008). The DNA repair system contains various reactions, such
as nucleotide excision repair, base excision repair, homologous
recombination (HR), and non-homologous end joining (NHEJ)
recombination pathways,mismatch repair pathways, and telomere
maintenance for genomic integrity, in all of which RecQ heli-
cases are considered to participate. Each member of the RecQ
helicase family may achieve speciﬁc tasks by interaction with
DNA repair pathway proteins (Hickson, 2003; Sharma et al., 2006)
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to cope with various types of DNA damage. Perhaps, accumu-
lation of DNA damages is the most serious problem for cells
because it causes cell mutagenesis, cell lethality, carcinogene-
sis, aging, and various other disorders. In this context, studies
with retrovirus integration into host chromosomes and compu-
tational simulation have clearly shown that a single unrepaired
DSB is sufﬁcient to kill a cell deﬁcient in DNA repair (Daniel
et al., 2001). Regulation of the cell cycle and genomic integrity
has also an important role in preventing carcinogenesis and
in acquiring chemo-resistant malignancy in cancer cells; conse-
quently, inhibition of these pathways in cancer cells provide a
viable approach to manage cancer therapy (Helleday et al., 2008;
Kelly and Fishel, 2008).
Among cellular DNA damage-responding elements, RecQ heli-
cases directly participate in a speciﬁcDNArepair pathway andhave
important roles in DNA damage signaling (Frei and Gasser, 2000;
Opresko et al., 2004; Pichierri et al., 2011). Based on the clariﬁed
roles of DNA helicases in the pathway of DNA repair in cancer
cells, a number of strategies are suggested to ﬁght against can-
cers by modulation of helicase activity (Gupta and Brosh, 2008;
Brosh, 2013).
In this review, we pay special attention to recent studies
on RECQL1-siRNA and WRN-siRNA that down-regulate the
expression of RECQL1 and WRN helicases, respectively, and
exert a tumor-speciﬁc killing effect on a wide range of tumor
cells.
INCREASED EXPRESSION OF RecQ HELICASES IN CANCER
CELLS
The expression of all RecQ helicases, except RECQL5, increases
when resting B cells of humans are transformed to rapidly grow-
ing B-lymphoblastoid cell line (LCL) cells by Epstein–Barr virus
(EBV) infection (Table 1). This high expression of RecQ heli-
cases seems to be coordinated with an increased growth rate
or with augmented malignancy of tumor cells (Kawabe et al.,
2000), and provides a basis for searching speciﬁc inhibitors of
individual RecQ helicases. The copy number of RECQL1 and
WRN helicases increases nearly 10-fold when B-LCLs are trans-
formed from a resting state to a rapidly growing state by EBV
infection, and then it is further increased several-fold after the
cells are transformed to an immortalized cell state in association
with a simultaneous expression of telomerase activity (Table 1).
This continuous up-regulation of RecQ protein expression in
malignant B-LCLs (up to nearly 100-fold) may reﬂect the need
of an increased DNA damage response to resolve replicative
lesions that arise in highly proliferative cell states, which may
occur in other cellular systems as a consequence of oncogene-
activated growth signals. Indeed, Slupianek et al. (2011) showed
that BCR-ABL induces WRN mRNA and protein expression by
c-MYC-mediated activation of transcription in chronic myeloid
leukemia cells. Alternatively, the increased expression of DNA
helicase may overcome the impaired checkpoint function of can-
cer cells that results from inactivation of relevant proteins by
mutation or are down-regulated by selection of cells in favor
of proliferation. Accordingly, inhibitors of helicase activity or
RNA interference (RNAi)-mediated acute depletion of helicase
should act as an intervention to increase replication lesions and
Table 1 | Copy number of RecQ helicases in resting B cells,
EBV-transformed LCL cells and telomerase-positive immortal LCL
cells.
Cells WRN BLM RTS RECQL1 RECQL5
Resting B cells
(N0008R)
1,200 330 120 2,100 340
Pre-immortal LCL
cells (N0008T)
94,000 27,000 1,100 15,000 330
Post-immortal LCL
cells (N68031M)
200,000 33,000 1,000 21,000 330
The copy number of each RecQ helicase was determined by quantitative
immunoblotting versus standard recombinant RecQ helicases. Each numeral rep-
resents a mean of duplicated samples. Reprinted from the paper by Kawabe et al.
(2000).
also leave DNA damage unrepaired to selectively kill cancer
cells. In fact, both speciﬁc small molecular weight inhibitors of
RecQ helicases (Aggarwal et al., 2011, 2013; Rosenthal et al., 2013;
Shadrick et al., 2013) and RNAi-mediated gene silencing with
siRNA suppress the growth of cancer cells in various model sys-
tems. In the following sections, we introduce both cases, while
placing a greater emphasis on the recently established RNAi-
mediated strategy that proved to act speciﬁcally on cancer cells
that contain impaired checkpoint functions and represent high
expressions of RecQ helicases (Futami et al., 2008a,c, 2010, Arai
et al., 2011; Mendoza-Maldonado et al., 2011, Sanada et al., 2013;
Tao et al., 2014).
MITOTIC CATASTROPHE IN CANCER CELLS INDUCED BY
RNAi-MEDIATED SILENCING OF RecQ HELICASES
In cancer chemotherapy, mitotic catastrophe is an important
mechanism required to induce cell death by anticancer geno-
toxic agents (Roninson et al., 2001; Nitta et al., 2004). Cancer
cells with an impaired G2 checkpoint function, including deﬁcien-
cies in p53, p21 and 14-3-3 activities, show increased sensitivity
to DNA-damaging agents, while normal cells that contain com-
petent G2 checkpoint activity are resistant to DNA damage
(Chan et al., 1999). Most cancer cells have a defective check-
point function, and so the cell cycle of cancer cells that have
DNA damage is transiently arrested at the metaphase without
segregation of chromosomes, and the arrested cells subsequently
undergo mitotic death. Attenuation of DNA repair capacity in
cancer cells is, therefore, an effective approach to selectively
kill cancer cells by using the differential capacity of check-
point function between normal and cancer cells (Figure 1).
Thus, inhibition of DNA repair may provide an opportunity
to selectively kill cancer cells by increasing the cytotoxicity of
DNA-damaging agents (and ionizing radiation) that is used for
chemotherapeutic intervention. Conventional cancer chemother-
apy drugs are used to induce excessive DNA damage beyond the
capacity of repair in cancer cells so that cancer cells undergo
cell death due to mitotic catastrophe caused by DNA damage
that remains unrepaired (Nitta et al., 2004). Mitotic catastro-
phe occurs in replicating cells that carry DNA damage through
cell cycle-mediated checkpoint regulation, and actively replicating
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FIGURE 1 | Increase in DNA damage in cancer cells by RECQL1
silencing. (A) Accumulation of DNA damage in RECQL1-siRNA treated
cells. Control siRNA(GL3-siRNA) treated HeLa cells (left panel) and
RECQL1-silenced HeLa cells (right panel) are shown. γH2AX, Detection of
DSB by staining with γH2AX antibody; SCE, sister chromatid exchange
regions shown by Δ. (B) Schematic representation of the mechanism
behind cancer cell-speciﬁc mitotic death by RECQL1 silencing with
RECQL1-siRNA. The boundaries set between the stage of cell cycles,
which are high in normal cells and low in cancer cells, represent an image
of the potency of checkpoint ability. G1, S, G2, and M are the stages of the
cell cycle. (C) Cancer cell-speciﬁc mitotic cell death induced by
RECQL1-siRNA. RECQL1 silencing in vitro was done in normal cells
(ARPE19 cells, left panel) and cancer cells ( HeLa cells, right panel) by
treatment with RECQL1-siRNA. Arrow heads show abnormal
chromosomes induced by RECQL1-siRNA transfection. In the right panel
(A–C) indicate the cells that died by mitotic catastrophe, M phase-arrested
cells and multinucleated cells, respectively. Parts of the data are reprinted
from the paper by Futami et al. (2008a).
cells are likely to be more sensitive to DNA damage than non-
replicating cells (Erenpreisa and Cragg, 2001; Vogel et al., 2007).
DNA damage formed endogenously during DNA replication
and additional DNA damage resulting from cancer chemother-
apy are all subjected to the cellular DNA repair system and are
removed if the repair system is not down-regulated. Inhibitors
of DNA repair pathways should augment the anticancer activ-
ity of chemotherapeutic drugs when such inhibitors are given in
combination with DNA-damaging drugs. As mentioned in a later
section, Futami et al. (2007) showed consistently thatWRN-siRNA
that silences the expression of WRN helicase and inhibits DNA
repair increases the chemotherapeutic activity of camptothecin
(CPT) in HeLa cells. DNA lesions that persist in the S-phase of the
cell cycle inhibit progression of replication forks, resulting even-
tually in the formation of replication-associated DSBs of DNA
(Figure 1A). Thus, the RecQ helicase-mediated repair mecha-
nism must help replicating cells to remove DSB stress and prevent
cells from chromosomal instability, permitting cell survival, and
proliferation.
APPLICATION OF siRNA FOR DEVELOPMENT OF INNOVATIVE
ANTICANCER THERAPEUTICS
Many conventional anti-cancer chemotherapeutic drugs are small
molecular weight compounds and are designed to cause DNA
damage in cancer cells, including 5-FU ﬂuorouracil nucleotides
(DNA modifying antimetabolite agents), CPT derivatives (topoi-
somerase inhibitors), platinum derivatives (DNA crosslinking
agents), Adriamycin or Doxorubicin (DNA intercalation), and
cyclophosphamide (DNA alkylation), bleomycin (DNA cleavage),
and mitomycin C (DNA crosslinking). Radiation therapy with
either X-ray or heavy ion irradiation causes cancer cells to have
DSBs by direct collision with DNA or by DNA oxidation with
hydroxyl radical ions derived from irradiated water molecules.
However, radiation therapy and DNA damaging chemicals used
in cancer chemotherapy have drawbacks by which such treat-
ments affect normal cells as well, often giving rise to severe
cytotoxic adverse effects. Long-term chemotherapy or radiother-
apy also induces cancer cells to become resistant to DNA damage
by increasing the ability to repair damaged DNA (Bouwman and
Jonkers, 2012).
As alternatives, siRNA drugs and micro-RNA (miRNA) drugs,
which use the principle of RNAi (Novina and Sharp, 2004), have
been considered as a new area of promise in anti-cancer ther-
apy (Duxbury et al., 2004; Zhou et al., 2006). The extremely high
speciﬁcity of siRNA to silence the expression of speciﬁed mRNA
targets has not only been reliably applied in a wide variety of
bio-medical research for gene silencing, but also has led to its
emergence as a novel class of pharmaceutical drugs. RNAi is a pow-
erful approach that can expand the anti-cancer strategy because
RNAi is a natural process that is not thought to perturb normal
cell physiology. Moreover, siRNA has outstanding pharmacolog-
ical properties (Vaishnaw et al., 2010) by which it can catalyze
the degradation of hybridized target mRNA, and, unlike other
low molecular weight compounds, it is stable in the cytoplasm of
transfected cells, existing in its intact structure for 1 week or more.
Thus, siRNAhas theproperties of (i) a high speciﬁcity inbinding to
target mRNA, (ii) a unique catalytic proﬁle in the mRNA degrada-
tion reaction and (iii) a stable biochemical nature in the cytoplasm
that permits effective siRNA concentrations as low as nanomo-
lar or less for more than a week, and (iv) siRNA transfection is
not too harmful to cells, such that siRNA-transfected cells could
be used to continue cell biological experiments. These excellent
properties of siRNA predict that siRNA therapeutics would
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not exert serious adverse effects on cancer-peripheral normal
cells.
We and others have tested candidate siRNA drugs that effec-
tively silence the expression of RecQ helicases to attenuate cellular
DNA repair activity. We studied the activity in vitro with cultured
cancer cells and in vivo with human cancer-bearing xenograft ani-
mal models (Futami et al., 2007, 2008a,c, 2010; Arai et al., 2011;
Mendoza-Maldonado et al., 2011; Tao et al., 2014). Recently, a
ﬁrst-in-man phase 1 trial was completed in the oncology ﬁeld
for a siRNA anti-hepatic cancer drug designed to silence two
different targets of vascular endothelial growth factor-A (VEGF-
A) and kinesin spindle protein (KSP) simultaneously (Tabernero
et al., 2013). In that study, siRNAs were formulated with lipid
nanoparticles and were administered by intravenous injection.
The results indicated that the siRNA-liposome complex is tol-
erated in humans, is incorporated in both hepatic cells and
tumor cells, and siRNA directs siRNA-sequence-matched cleav-
age of VEGF and KSP mRNAs in the cytoplasm of cells. This
pioneering phase1 clinical study provided pharmacodynamics
data that conﬁrmed a safe siRNA-liposome complex and target
mRNA-speciﬁc down-regulation in cancer cells. All these stud-
ies paved the way to make siRNA drugs truly realistic in the near
future.
In the initial studies with a drug-oriented siRNA applica-
tion, siRNAs were recognized to activate innate immune cells by
Toll-like receptors, resulting in potent cytokine induction and
immunotoxicity (Judge et al., 2005). This immune-stimulatory
effect, generally associated with RNA, was thought to impair the
development of RNA therapeutics. However, subsequent efforts
clariﬁed that immune recognition of siRNA is sequence-speciﬁc
and is moderated by facilitating sequence design or by appropriate
chemical modiﬁcation of 2′-O-methylation at ribose moiety or
both that ameliorates the immune response (Hamm et al., 2010).
RECQL1 HELICASE AS THE TARGET OF ANTICANCER
THERAPY
BIOLOGICAL FUNCTIONS OF RECQL1 HELICASE
Of the ﬁve human RecQ helicase members, RECQL1 helicase
was characterized for the ﬁrst time after isolation from human
cancer cells and was named RECQL1 after E. coli RecQ (i.e.,
RECQ-like human helicase number 1; Seki et al., 1994). Bio-
chemical and cell biological data show that RECQL1 helicase
unwinds DNA in vitro ATP-dependently, catalyzes base-matching
ATP-independently (Cui et al., 2003, 2004) and resolves Holliday
junctions during DNA replication in cell proliferation (Doherty
et al., 2005; LeRoy et al., 2005). RECQL1 is assumed to have a
role in DNA mismatch repair together with the human EXO1
andMSH2-MSH6mismatch repair recognition complex (Doherty
et al., 2005). Popuri et al. (2014) recently found that human
RECQL1 participates in telomere maintenance.
RECQL1 is expressed ubiquitously in a wide variety of cells
and tissues participating in maintaining the genomic integrity
of cells. It is highly up-regulated in rapidly proliferating cells,
particularly in carcinoma cells originating from various organs,
including lung, liver, pancreas, colon, brain, ovary, and head-
and-neck cancers (Futami et al., 2008a,c, 2010; Arai et al., 2011;
Mendoza-Maldonado et al., 2011; Sanada et al., 2013; Tao et al.,
2014). Acute depletion of human RECQL1 by RNAi renders cells
sensitive to DNA damage and results in spontaneous increase
in DSB-mediated gamma-H2AX foci and increased sister chro-
matid exchanges (SCEs), suggesting an abrogation of DNA repair
(Figure 1A; Sharma et al., 2007; Futami et al., 2008a). Growth
arrest in cancer cells by RECQL1 depletion is characterized by
accumulation of unrepaired DNA damage and arrested cells at
the G2 or M cell cycle phases, resulting in mitotic cell death and
eventual decreased proliferation (Figures 1A,C).
As expected, RECQL1-silencing by RNAi technology also made
cancer cells sensitive to genotoxic drugs in vitro (Arai et al., 2011).
Mendoza-Maldonado et al. (2011) showed that human RECQL1
is highly expressed in biopsied glioblastoma tissues paralleled by
a lower expression of perilesional control cells in non-dividing
tissues. They showed that acute depletion of RECQL1 by RNAi
results in a signiﬁcant reduction of cell proliferation, pertur-
bation of S-phase progression and an increase in spontaneous
gamma-H2AX foci formation in glioblastoma cells, which become
hypersensitive to anti-brain tumor drug HU or temozolomide
treatment. Berti et al. (2013) showed that RECQL1 helicase has
a speciﬁc role not shared with other DNA helicases in the restart
of stalled replication forks induced by CPT, the reaction of which
could be utilized as a new target in the search for anti-cancer
drugs. Although RECQL1-deﬁcient mice are indistinguishable
from wild-type mice, their embryonic ﬁbroblasts are sensitive to
ionizing radiation (Sharma and Brosh, 2007, 2008). The function
of RECQL1 helicase seems to be non-essential and complemen-
tary with other DNA repair helicases, because no human disease
is known to correlate with mutations in the RECQL1 gene.
Individual variations in DNA repair capacity affects the clin-
ical response to cytotoxic cancer therapy and overall survival of
patients. Li et al. (2006a,b) and Cotton et al. (2009) found that
polymorphism of A159C SNP at the 3′-untranslated region in
RECQL1 genes signiﬁcantly affect the overall survival of patients
with resectable pancreatic cancer who were treated with adju-
vant or neoadjuvant chemoradiation using gemcitabine as the
radiosensor. Why the polymorphism at the non-coding region
of mRNA affects the clinical progonosis of patients is not clear,
but A159C SNP may function as a binding site for regula-
tory molecules that affect either splicing, translation efﬁciency,
or stability of RECQL1 mRNA. In this case, the gemcitabine
and radiation-induced DNA damage is likely to be repaired by
the RECQL1-mediated pathway; patients with the AA genotype
with A159C polymorphism showed a signiﬁcantly longer sur-
vival time than those with the CC genotype, suggesting that
cancer cell species having the AA genotype are sensitive to DNA
damage stress, perhaps due to a reduced expression of RECQL1
helicase.
DNA repair has been termed a double-edged sword because
decreased DNA repair may increase the risk of developing cancer,
but, on the other hand, the decreased DNA repair of cancer cells
improves survival in patients when treated with DNA-damaging
agents. Generally, however, RECQL1 and other helicase genes
are not mutated or are epigenetically down-regulated in tumor
cells, and instead expression is most often up-regulated (Kawabe
et al., 2000; Futami et al., 2008a,b,c, 2010; Sanada et al., 2013).
Thus, RecQ helicases may be important survival factors for many
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tumors. The role of RecQ helicases in response to replication
stress suggests an ideal molecular target to selectively eliminate
malignant tumor cells by combined therapy with siRNA and
cancer chemotherapeutic agents.
IMMUNOHISTOCHEMICAL ANALYSIS OF RECQL1 EXPRESSIONS IN
CANCERS AND ITS RELATIONSHIP TO CLINICOPATHOLOGICAL
FEATURES OF CANCERS
The expression level of RECQL1 protein in hepato-cellular carci-
noma (HCC) cells obtained clinically was investigated to know
if the expression level of RECQL1 helicase is directly related
to the differentiation stage of HCC cells, malignancy of can-
cer cells and prognosis of patients (Futami et al., 2010). In the
relationship between RECQL1 expression and clinicopathological
features, RECQL1 expression (i) signiﬁcantly correlateswith histo-
logical grade and MIB-1 indices of HCC, (ii) is signiﬁcantly higher
in simple nodular type HCC than extranodular type HCC, (iii) is
signiﬁcantly higher in HCC with portal vein invasion than in HCC
without portal vein invasion, and (iv) is higher in HCC nodules
of diameter ≥2.0 cm than in HCC nodules of diameter <2.0 cm.
These data showed that RECQL1 could be used as a molecular
marker to evaluate the malignancy of HCC, although RECQL1
expression and other clinicopathological features in ovary can-
cers do not seem to relate to prognosis, including recurrence, and
survival time of patients.
In the case of ovarian cancers, an immunohistochemical study
was done to test if RECQL1 expression in cancer cells can diagnose
the type of cancer, such as serous type, endometrioid type, clear
cell type, and mucinous type (Sanada et al., 2013). The data of that
study showed that RECQL1 expression cannot distinguish type of
ovarian cancer, although a trend suggests that a high expression
associates with serous type and endometrical type cancers rather
than with clear cell type and mucinous type cancers.
ANTICANCER EFFECT OF RECQL1-siRNA/DDS IN VITRO AND IN VIVO
RECQL1-targeted siRNA suppresses the growth of a wide range of
cultured tumor cells at low concentrations around 10 nM. Micro-
scopic analysis showed that growth suppression is mainly due to
mitotic cell death after the cell cycling is arrested at the M phase
(Futami et al., 2008a, 2010). A few populations of cancer cells that
survive mitotic death undergo morphological changes to non-
dividing large cells that resemble the morphology of senescent
cells. Notably, this same treatment with RECQL1-siRNA does not
kill normal cells, such as ARPE-19, TIG3,WI38, and HUVEC cells
that grow rapidly, although normal cells treated with RECQL1-
siRNA slightly slow the growth rate. Thus, these experiments
showed that cancer cells are extremely sensitive to depletion of
RECQL1 and that cell growth is severely inhibited, as if the growth
of cancer cells is dependent on a high expression of RECQL1, but
non-cancerous cells and all normal cells tested are unaffected by
RNAi-mediated acute depletion of RECQL1 helicase. This event
was characterized as mitotic catastrophe that occurs during the
cell cycle of cancer cells deﬁcient in the checkpoint system due to
accumulation of DNA damage caused by the absence of RECQL1
helicase (Futami et al., 2008a,c, 2010).
To apply this speciﬁc killing of cancer cells for clinical beneﬁt in
anticancer chemotherapy, a series of experiments were carried out
with model mice inoculated with various human cancer cells and
RECQL1-siRNA formulatedwith cationic liposomeLIC-101(Yano
et al., 2004). The results showed that RECQL1-targeted siRNA
can suppress tumor growth in many mouse xenograft models,
including lung, liver, pancreatic, colorectal cancer models and in
orthotropic hepatic cancer models (Figure 2A), as well as in nude
mice that have head and neck carcinoma (Futami et al., 2008a,c,
2010; Arai et al., 2011). Here, RECQL1-siRNA formulated with
cationic liposome LIC-101 did not show any noticeable adverse
effects.
In addition,RECQL1-siRNA increases the anticancer activity of
cis-platinum (II) diamine dichloride (CDDP), a DNA-damaging
cancer therapeutic, when they are administered together in a
murine model of hypopharyngeal xenografts that had been inoc-
ulated with notorious FaDu cancer cells. This co-treatment of
RECQL1-siRNA with CDDP increases DNA damage and cancer
cell death (Figure 2B; Arai et al., 2011). Thus, the anticancer strat-
egy using siRNA to attenuate the DNA repair function in cancer
cells is not only superb by itself in suppressing cancer cell growth
through mitotic catastrophe, but also the simultaneous treatment
of genotoxic agents increases DNA damage and thus increases the
efﬁcacy of anticancer chemotherapy. Recently, Tao et al. (2014)
conﬁrmed that RECQL1 silencing by overproduction of miR-203,
an miRNA that suppresses the expression of RECQL1, also leads
to a strong anticancer effect on squamous carcinoma cells both
in vitro and in vivo.
All these results clearly showed that RECQL1 helicase protein
andRECQL1mRNAare excellent targets for cancer chemotherapy,
and that RECQL1-siRNA formulated with liposome, such as LIC-
101 liposome as a drug delivery system (DDS), is a promising
anticancer drug candidate. Selection of DDS, however, remains
to be a key issue in the development of potential siRNA drugs,
because it helps protect siRNA from degradation by ribonucleases
and delivers siRNA to speciﬁed tissues, organs, and cells.
WRN HELICASE AS THE TARGET FOR ANTICANCER THERAPY
BIOLOGICAL FUNCTION OF WRN AS DEDUCED FROM ABERRANT DNA
METABOLISM IN CELLS FROM WS PATIENTS
Werner syndrome is an autosomal recessive disease characterized
by premature aging and a high incidence of malignant neoplasms.
The causative geneWRN was identiﬁed as coding forDNAhelicase
belonging to the RecQ helicase family (Yu et al., 1996). The WRN
protein (WRN) contains 3′->5′ exonuclease at the N-terminal
region in addition to 3′->5′ DNA unwinding helicase activity,
implicating its biological function in maintaining genomic sta-
bility by DNA repair. The biological function of each helicase in
the RecQ family can be deduced from the outcome of aberrant
DNA metabolism seen in patient cells that lack a particular RecQ
helicase. In the case of WRN helicase, chromosomal instability
associated with increased somatic mutation, large DNA deletions
(Fukuchi et al., 1989) and unusual dynamics in telomere shorten-
ing (Tahara et al., 1997; Sugimoto, 2014) have been found in cells
from WS patients, suggesting that WRN may participate in the
repair of DSB through HR and NHEJ repair pathways. Because
WS patients are highly predisposed to tumorigenesis, showing a
particularly higher incidence of non-epithelial tumors such as soft-
tissue sarcoma and benign meningioma than epithelial carcinoma
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FIGURE 2 | Anticancer effects of RECQL1-siRNA andWRN-siRNA.
(A)Time course experiments measuring the inhibitory effect of the
RECQL1-siRNA-LIC101 complex on the growth of Hep3B cancer nodules.
Open squares, red triangles and closed circles show mice treated with 10%
maltose solution as a control, NS(non-silencing)-siRNA/LIC101 complex and
RECQL1-siRNA/LIC101 complex, respectively. Arrow heads represent
injections made subcutaneously into cancer-bearing mice. The anticancer
effect of RECQL1-siRNA/LIC101 on Hep3B cancer-bearing mice is
represented visually. Panels (A–C) represent the size of cancer nodules
grown until 42 days after inoculation. Reprinted from the paper by Futami
et al. (2008b). (B) Anticancer effects of locally injectedWRN-siRNA and
RECQL1-siRNA on head and neck squamous cell carcinoma, and the
synergistic effect made by the simultaneously intravenously injected
genotoxic platinum drug CDDP. Therapeutic effects ofWRN-siRNA and
RECQL1-siRNA, and the combined effect with CDDP were examined in
human FaDu carcinoma-bearing mouse xenografts. NC, no siRNA addition;
GL3, GL3-siRNA; RECQL1, RECQL1-siRNA;WRN,WRN-siRNA. The right
panel shows immunohistochemical evaluations ofWRN and RECQL1 proteins
expressed in surgically isolated cancerous regions of a human FaDu
carcinoma-bearing xenograft mouse model after treatment with injections of
the siRNA-atelocollagen complex. GL3-siRNA represents control siRNA that
does not inhibit the expression ofWRN or RECQL1 helicases.WRN-siRNA
and RECQL1-siRNA treatments reduced the expression ofWRN and RECQL1
proteins, respectively, stained by speciﬁc antibodies. Reprinted from the
paper by Arai et al. (2011) by courtesy of those authors. (C) Increased
cytotoxicity of anticancer drug camptothecin (CPT) in cancer cells by
co-treatment withWRN-siRNA. HeLa cells were transfected with a sub-lethal
concentration ofWRN-siRNA and were treated with a serial dilutions of CPT
added after transfection. After 48 h of culture, the cell viability was monitored.
Reprinted from the paper by Futami et al. (2007). The half-lethal dose (LD
50%) of CPT was reduced by nearly ten-fold by treatment withWRN-siRNA
(10 μM). Reprinted from the paper by Futami et al. (2007).
that are seen frequently in normal subjects (Goto et al., 1996),
we hypothesized that WRN helicase could be a tumor suppressor
in normal subjects that prevents tumorigenesis of non-epithelial
cells and is required for the growth of carcinoma of epithelial
origin (Futami et al., 2008b). Earlier studies have clariﬁed that
most mutations in WS patients generate the premature termina-
tion codon in WRN mRNA that explains the basis of the loss of
function of the WRN gene in WS patients (review by Shimamoto
et al., 2004).
In the case of the expression of RecQ helicases, ﬁve RecQ
helicase genes appear to be transcribed to mRNAs differentially
depending on the organ or tissue in normal subjects. WRN seems
to be expressed more or less tissue-speciﬁcally in pancreas, testis
and ovary, but RECQL1 is expressed ubiquitously in all tissues
(Kitao et al., 1998). Therefore, genomic instability in WS patients
caused by the loss of WRN function is predicted to occur severely
in tissues where WRN protein is most efﬁciently expressed in nor-
mal subjects. The characteristic clinical symptoms of WS patients,
such as diabetes mellitus and early hypogonadism in both male
and female WS patients, correspond well to organs in which
WRN helicases are expressed highly in normal subjects. In those
tissues or organs, DNA damage generated endogenously during
Frontiers in Genetics | Genetics of Aging January 2015 | Volume 5 | Article 441 | 6
Futami and Furuichi RecQ helicases as anti-cancer targets
DNA replication is not repaired in WS patients due to lack of the
functional WRN protein. A functional relationship seems to exist
between WRN and the replication checkpoint in normal cells, but
an inability of this crosstalk might contribute to induce genomic
instability, a common feature in senescent cells and cancer cells.
In the absence of functional WRN, a series of correlated out-
comes occurs, including replication arrest during cell cycling, slow
growth in cell proliferation, and incomplete DNA repair resulting
in many genomic deletions, all of which result in a decrease in
number of cells leading to deterioration of speciﬁed tissues rep-
resenting premature aging phenotypes referred to as segmental
progeroid syndrome (Martin, 1985).
ROLE OF WRN HELICASE IN TUMORIGENESIS
Transcription of theWRN gene is directed by a house-keeping SP1
promotor. An in vitropromotor analysis showed thatWRNexpres-
sion is attenuatedby tumor suppressor p53protein, suggesting that
WRN protein, which shows a putative tumor suppressor function,
decreases in p53-enriched senesced cells (Yamabe et al., 1998).
In this context, Agrelo et al. (2006) showed that WRN function
is abrogated in human colorectal cancer cells by transcriptional
silencing associated with CpG island-promoter hypermethylation.
Restoration of WRN expression by in vitro demethylation of pro-
motor or by reintroduction of WRN into cancer cells induces
tumor-suppressor-like features, such as reduced density of colony
formation and inhibition of tumor growth, in mouse xenograft
models. Analysis of many human primary tumors showed that
hypermethylation of the WRN promotor is a common event in
various tumor cells and is indicative of tumorigenesis by the
absence of WRN expression. Agrelo et al. (2006) concluded that
these ﬁndings underline the signiﬁcance of WRN as a caretaker
of a genome that has tumor-suppressor activity and they identify
epigenetic silencing of WRN as a key step to cancer development.
Decreased WRN expression may cause genomic instability in nor-
mal cells and induce initial tumorigenesis, but malignant tumor
cells would acquire increased levels of WRN expression to protect
their own genomic stability. Malignant tumor cell lines from var-
ious sources show a high expression of WRN helicase. In the case
of colorectal cancer, the presence of aberrant hypermethylation of
the WRN promotor in cancer cells predicts improved survival in
patients treated with a CPT derivative irinotecan, a topoisomerase
inhibitor used in therapeutics of this neoplasm, because decreased
WRN makes neoplasmic cells sensitive to a DSB-inducing geno-
toxic agent (Agrelo et al., 2006). WS patients have a high frequency
of having non-epithelial tumors than epithelial carcinoma, but
the underlying reason remains to be clariﬁed. However, a high
WRN expression may possibly be a prerequisite to maintain
genomic integrity in rapidly growing carcinoma cells in normal
subjects.
Futami et al. (2007) showed that WRN-siRNA abrogates the
DNA repair activity of HeLa cells and increases the sensitiv-
ity to topoisomerase inhibitor CPT. In this case, the silencing
of WRN helicase prevents the repair of CPT-induced DNA
damage and permits accumulation of unrepaired DNA dam-
age that explains increased cytotoxicity of CPT in the com-
bined treatment of CPT and WRN-siRNA (Figure 2C). The
data also explained why WS patient cells also show increased
sensitivity to other genotoxic reagents, including CPT, etopo-
side, 4NQO, and bleomycin (Sakamoto et al., 2001). Recently,
Aggarwal et al. (2011) used small molecular weight compound
NSC19630 that inhibits WRN activity in anti-cancer cell biol-
ogy experiments. Exposure of human cancer cells to NSC 19630
dramatically impairs growth and proliferation, induces apopto-
sis WRN-dependently and results in increased γ-H2AX reactive
chromosomal DSB, similar to the results obtained by Futami
et al. (2007) by silencing WRN with siRNA treatment. NSC
19630 exposure leads to delayed S-phase progression, consis-
tent with accumulation of stalled replication forks, and to DNA
damage WRN-dependently. Exposure to NSC 19630 sensitizes
cancer cells to the G4-binding compound telomestatin or to a
poly(ADP-ribose) polymerase (PARP) inhibitor. Sublethal dosage
of NSC 19630 and the chemotherapy drug topotecan acts syn-
ergistically to inhibit cell proliferation and induce DNA damage
(Aggarwal et al., 2011). The use of this WRN helicase inhibitor
(NSC 19630) may provide insight into the importance of WRN-
mediatedpathways important forDNArepair and the replicational
stress response.
ANTICANCER EFFECT OF WRN-siRNA/DDS IN VITRO AND IN VIVO
Both WRN and RECQL1 helicases are expressed highly in head
and neck squamous carcinoma cells (HNSCCs; Figure 2B), and
siRNA-mediated silencing of either gene suppresses growth of
HNSCC in vitro (Arai et al., 2011). Similarly, local injections of
WRN-siRNA and RECQL1-siRNA formulated with atelocolla-
gen into a mouse zenograft model of hypopharyngeal carcinoma
markedly inhibits tumor growth. A combination of either siRNA
with CDDP, a genotoxic drug commonly used in HNSCC treat-
ment, signiﬁcantly augments the in vivo anticancer effect of CDDP
(Figure 2B). Notably, no recurrencewas observed for some tumors
after siRNA and CDDP treatment in this model. These ﬁndings
offer a preclinical proof of WRN and RECQL1 helicase as novel
therapeutic targets to treat aggressive HNSCC and possibly other
cancers.
Several lines of evidence suggest that WRN helicase has an
important role in DNA replication and S-phase progression
(review by Croteau et al., 2014). Loss of WRN markedly extends
the time of cell cycles after genotoxic treatments. This result
comﬁrmed the importance of WRN during genomic replica-
tion, and indicated that WRN acts to facilitate fork progres-
sion after DNA damage or replication arrest. Recent studies
showed that conditional gene silencing of WRN expression in
non-small-cell lung cancer xenografts that are over-expressed
with c-MYC inhibits tumor growth, suggesting that target-
ing WRN protein inhibits growth of c-MYC-associated can-
cers (Moser et al., 2012). A growing body of evidence shows
that WRN functions in close connection with the replica-
tion checkpoint that includes both ataxia telangiectasia mutated
(ATM) protein and ATM-Rad3-related (ATR) kinase activities
and maintains fork integrity and re-establishment of fork pro-
gression. Recent ﬁndings also support the view that ATR and
ATM kinases modulate WRN function at deﬁned steps of the
response to replication fork arrest. Or vice versa, WRN may be
required to activate ATM kinase and the intra-S-phase check-
point in response to DNA interstrand crosslink-induced DSBs
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and other forms of fork arrest (Cheng et al., 2008; Pichierri
et al., 2011). WRN is speculated to be a DNA helicase that efﬁ-
ciently unwinds G4 DNA and other forms of alternative DNA
structures, such as telomeric displacement loops. These data
indicate that DNA repair helicases, such as RECQL1 and WRN,
represent a novel class of important targets required for anti-
cancer therapy. Inhibition of their activities either by siRNA
or by small molecular weight compounds in cancer cells hav-
ing checkpoint mutation should give rise to a new type of
anticancer therapeutic drug that also permits strong synergis-
tic anticancer effects when combined with genotoxic drugs as
depicted in Figure 2B (with CDDP) and Figure 2C (with CPT;
Futami et al., 2007; Arai et al., 2011).
BLM, RTS, AND RECQL5 HELICASES ARE POTENTIAL
TARGETS OF ANTICANCER THERAPY
Patients of BLM and a subset of patients with RTS who lack
functional BLM and RTS helicases, respectively, manifest clini-
cal phenotypes of genomic instability and a high incidence of
cancers (Ellis et al., 1995; Lindor et al., 2000). Like WRN, heli-
case genes BLM and RTS are suggested to function as tumor
suppressor genes in normal individuals. Both BLM and RTS are
expressed highly in rapidly growing EBV-infected LCL cells from
normal individuals, and the expression of BLM is, like WRN, fur-
ther augmented when EBV-transformed cells are differentiated
to telomerase-positive immortal cells (Table 1). In a pioneering
effort to ﬁnd an antiproliferative drug,Nguyen et al. (2013) discov-
ered small molecular weight compound ML216 from a screening
of a chemical compound library that inhibits the DNA bind-
ing activity of BLM in vitro (IC50% ∼3 uM) and abrogates the
unwinding activity of BLM on a forked DNA duplex. As expected,
ML216 increased the rate of SCE in culturedhumanﬁbroblasts and
increased the sensitivity to aphidicolin, an inhibitor of replicative
DNA polymerases (Banerjee et al., 2013; Rosenthal et al., 2013).
However, ML216 does not seem to be highly speciﬁc to BLM heli-
case, because it also inhibits DNA unwinding activity of WRN
(Banerjee et al., 2013). Further, pharmacological studies may be
needed to improve the speciﬁcity and efﬁcacy before ML216 is
tested for clinical application.
Mao et al. (2010) showed that depletion of BLM by RNAi-
mediated shRNA gene silencing suppresses the growth of osteosar-
coma U2OS cell line with an increase in DNA damage detected
by gamma-H2AX, suggesting that BLM is a potential target for
anticancer therapeutics. They also showed depletion of BLM and
WRN by shRNA from U2OS and normal ﬁbroblast sensitized cells
to dose-dependent killing by CPT, CDDP and 5-FU, consistent
with previous observations by Futami et al. (2007) in whichWRN-
siRNA treatment sensitized HeLa cells to CPT and lowered the
cytotoxic dose by nearly 10-fold.
Few reports exist of RTS and RECQL5 helicases as possible
cancer targets. However, Su et al. (2010) elegantly showed that
RECQL4 (RTS) helicase has critical roles in prostate carcino-
genesis, and that RNAi-mediated gene suppression reduces the
growth and survival of metastatic prostate cancer cells. In addi-
tion, RECQL4-suppressed cells treatedwith siRNA show increased
apoptotic death after treatment with ultraviolet C and γ-ray radi-
ation. Thus, Su et al. (2010) conclude that RECQL4 protects the
genomic integrity of prostate cancer cells from endogenous and
exogenous DNA damage, similar to our discussion above with
RECQL1. In fact, RECQL4-depleted prostate cancer cells undergo
extensive apoptotic death in PARP -1-dependently in vitro and
show reduced tumorigenicity in nude mice in vivo. Because the
expression of RECQL4 increased highly inmetastatic prostate can-
cer cells and in tumor tissue, RECQL4 protein could be used as
new tumor marker.
While much insight has been gained into the function of
WRN and BLM, little is known about RECQL5. Three iso-
mers result from differential splicing from the RecQ gene tran-
script. The largest molecule, RECQL5, localizes to the nucleus,
whereas the two smaller molecules are found in the cytoplasm
(Shimamoto et al., 2000). Nuclear RECQL5has a role inmaintain-
ing genomic stability by cooperating with topoisomerase II(alpha)
in DNA decatenation and cell cycle progression (Ramamoorthy
et al., 2012). Because RECQL5- depleted cells show slow prolifer-
ation, G2 and M cell cycle arrests and late S-phase cycling defects,
resulting in entangled abnormal chromosomes at the M phase,
possibly RECQL5 could be challenged, like RECQL1, as a new
cancer therapeutic target.
PERSPECTIVE
The relation between helicases and DNA damage response and
genomic stability suggests that DNA repair helicases may be suit-
able targets for cancer chemotherapy (Helleday et al., 2008). Most
cancer cells are deﬁcient in G1 and G2 checkpoint function and
fail to arrest the cell cycle at G1 and G2 phases to engage in
DNA repair. Instead, cells that proceed in the cell cycle to the
M phase, where DNA repair is no longer permitted, eventually
undergo cell death as they enter mitosis (Nitta et al., 2004). Sev-
eral studies have reported a greater efﬁcacy in the therapeutic
application of siRNA against malignant tumors in combination
with other chemotherapeutic agents, such as with gemcitabine
together with ribonucleotide reductase-siRNA (Duxbury et al.,
2004), CPT together with WRN helicase-siRNA (Futami et al.,
2007) and Adriamycin together with survivin-siRNA (Yonesaka
et al., 2006). Such approaches of targeting RecQ helicases with
a strict speciﬁcity, such as by gene silencing with siRNA, would
be most conspicuous in cooperation with DNA damaging agents
or radiation. Thus, DNA repair helicases expressed highly in
most malignant and rapidly proliferating cancer cells not only
provide new proliferative protein markers, such as WRN and
RECQL1 proteins (Figure 2), but also provide logical conse-
quences for combination therapy to ﬁght against drug-resistant
cancer cells.
In conclusion, DNA repair helicases are ideal molecular targets
for anticancer drug discovery, and, in particular, RECQL1-siRNA
and WRN-siRNA and perhaps BLM-siRNA and RTS-siRNA are
promising new therapeutic interventions against malignant can-
cers of various histological and clinical characteristics, including,
for example, those of the platinum-resistant, CPT-resistant, and
5-FU-resistant subtypes.
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